ADC Therapeutics (ADCT) Receivables - Net (2021 - 2026)
ADC Therapeutics (ADCT) posted Receivables - Net of $31.0 million for Q1 2026, up 6.62% sequentially from $29.1 million in Q4 2025, and down 2.26% YoY from $31.8 million in Q1 2025.
ADC Therapeutics (ADCT) Receivables - Net (2021 - 2026) Analysis & Trends
ADC Therapeutics has reported Receivables - Net for 6 years, with the latest figure at $31.0 million in Q1 2026.
- Quarterly Receivables - Net fell 2.26% year-over-year to $31.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.0 million (down 2.26% YoY) and the FY2025 annual result came in at $29.1 million, up 43.32% from the prior year.
- Receivables - Net grew to $31.0 million in Q1 2026 per ADCT's latest filing, from $29.1 million in the prior quarter.
- Over five years, Receivables - Net peaked at $73.0 million in Q4 2022 and troughed at $20.3 million in Q4 2024.
- A 5-year average of $27.6 million and a median of $24.0 million in 2024 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2023: Receivables - Net surged 903.51% in 2022, then slumped 65.49% in 2023.
- Over 5 years, Receivables - Net stood at $73.0 million in 2022, then plunged by 65.49% to $25.2 million in 2023, then fell by 19.32% to $20.3 million in 2024, then jumped by 43.32% to $29.1 million in 2025, then grew by 6.62% to $31.0 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $31.0 million, $29.1 million, and $22.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.04 Mn |
| Jun 30, 2026 | 28.04 Mn |
| Mar 31, 2026 | 31.05 Mn |
| Mar 31, 2026 | 31.05 Mn |
| Dec 31, 2025 | 29.12 Mn |
| Dec 31, 2025 | 29.12 Mn |
| Sep 30, 2025 | 22.92 Mn |
| Sep 30, 2025 | 22.92 Mn |
| Jun 30, 2025 | 26.18 Mn |
| Jun 30, 2025 | 26.18 Mn |
| Mar 31, 2025 | 31.76 Mn |
| Mar 31, 2025 | 31.76 Mn |
| Dec 31, 2024 | 20.32 Mn |
| Dec 31, 2024 | 20.32 Mn |
| Sep 30, 2024 | 24.03 Mn |
| Sep 30, 2024 | 24.03 Mn |
| Jun 30, 2024 | 22.87 Mn |
| Jun 30, 2024 | 22.87 Mn |
| Mar 31, 2024 | 23.19 Mn |
| Mar 31, 2024 | 23.19 Mn |